Michael N. Cohen, MD, FAAO, retinal surgeon at Wills Eye Hospital in Philadephia and Mid Atlantic Retina, speaks about the future of gene therapy and the accessibility and availability of these therapies moving forward.
Michael N. Cohen, MD, FAAO, retinal surgeon at Wills Eye Hospital in Philadephia and Mid Atlantic Retina, speaks about the future of gene therapy and the accessibility and availability of these therapies moving forward.
Transcript
What needs to be done to ensure that new gene therapies for retinal diseases are accessible and affordable for all patients?
So I think that's a great question, and the complexities of that answer are pretty deep. Ultimately, I think we have to make sure first that we have an effective medicine. Right now, it's really promising, and these phase 1 results up to 24 months in our safety and tolerability study look very good. And we look forward to a forthcoming phase 2 efficacy trial, looking at our medicine as a treatment for GA [geographic atrophy] in a patient with AMD [age-related macular degeneration].
More broadly, I think it's important to consider not just the impact that these medications with gene therapy have on the patients and in our case, their visual functioning, but also the potential elimination of some of the other burdens of the other treatments that could potentially be available. I think those are all important things to consider.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More